Abstract
The author would like to report an error that appeared under the section Need for new US testing strategies in a recently published article [1]. The sentence ‘Compared with pegylated interferon/ribavirin therapy alone, the addition of telaprevir or boceprevir to the treatment regimen has increased the potential for viral clearance from 38% to 63% and 46% to 79%, respectively [26,27], improving health outcomes for individuals living with HCV infection and preventing ongoing disease transmission’ should appear as ‘Compared with pegylated interferon/ribavirin therapy alone, the addition of boceprevir or telaprevir to the treatment regimen has increased the potential for viral clearance from 38% to 63% and 46% to 79%, respectively [26,27], improving health outcomes for individuals living with HCV infection and preventing ongoing disease transmission’. The author apologizes for this error.